EARLY COGNITIVE IMPAIRMENTS IN YOUNG HYPERTENSIVE PATIENTS

Download full text PDF
Issue: 
1
Year: 
2016

S. Duma, Candidate of Medical Sciences; L. Shcherbakova Research Institute of Therapy and Preventive Medicine, Novosibirsk

The authors evaluate the efficiency of a set of procedures for the early diagnosis of cognitive impairments in young and middle-aged hypertensive patients and the abilities of piribedil (Pronoran) and agomelatine (Valdoxan) in their treatment.
Keywords: 
cognitive impairments
hypertension
diagnosis
therapy
piribedil
agomelatine
Pronoran
Valdoxan

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Ostroumova O.N. Kognitivnye funktsii – novaja «mishen'» dlja terapii u patsientov s gipertonicheskoj bolezn'ju // Vrach. – 2011; 5: 2–4.
  2. Chelysheva I.A., Nagornyj N.S. Nejropsihologicheskie i nejrovizuali zatsionnye aspekty distsirkuljatornoj entsefalopatii v rakurse strukturno-funktsional'noj modeli golovnogo mozga // Zhurn. nevrol i psihiatr. – 2005; 105 (1): 65–9
  3. Zaharov V.V., Jahno N.N. Narushenija pamjati. Nejropsihologicheskie testy. Neobhodimost' i vozmozhnost' primenenija / M.: GEOTAR-Media, 2003; s. 150.
  4. Gustov A.V., Mel'nikova T.V., Guzanova E.V. Sindromy narushenija psihicheskih funktsij v nevrologicheskoj praktike: uchebnoe posobie / N. Novgorod, 2005.
  5. Duma S.N. Otnoshenie vrachej pervichnogo zvena k rannej diagnostiki i 5. lecheniju kognitivnyh narushenij // Psihicheskie rasstrojstva v obschej medi-tsine. – 2011; 3: 60–4.
  6. Glozman Zh.M. Kolichestvennaja otsenka dannyh nejropsihologicheskogo issledovanija / M., 1999; 160 s.
  7. Lurija A.R.Vysshie korkovye funktsii cheloveka i ih narushenija pri lokal'nyh porazhenijah mozga / M.: MGU, 1969; 504 s.
  8. Panasjuk A.Ju. Adaptirovannyj variant metodiki D. Vekslera / M.: NII psihiatrii, 1983; s. 79.
  9. Jahno N.N., Zaharov V.V. Lechenie nedementnyh kognitivnyh narushenij u patsientov s arterial'noj gipertenziej i tserebral'nym aterosklerozom // Nevrol. zhurn. – 2012; 4: 12–6.
  10. Preobrazhenskaja I.S. Umerennye kognitivnye rasstrojstva: diagno stika i lechenie // Consilium Medicum. – 2008; 1: 23–8.
  11. Golomb J., Kluger A., Garrard P. et al. Clinicians Manuel on Mild Cognitive Impairment Science / London: Press Ltd, 2001; 56
  12. Avedisova A.S. Rezul'taty issledovanija DZhAZ // Zhurn. im. Gannushkina. – 2013; 6: 4–13.
  13. Kasper S., Corruble E., Hal A. et al. Antidepressant efficacy of agomelatine versus SSRI/SNRI: results from a pooled analysis of head-to-head studies without a placebo control // Int. Clin. Psychpharmacol. – 2013; 28 (1): 12–9.
  14. Ivanov S.V. Po rezul'tatam programmy HRONOS // Psihiatrija i psi hofarmakologija. – 2009; 6: 15–9.
  15. Sizova Zh.M., Lapidus N.I., Bajchorov I.H. Opyt primenenija Pronorana dlja korrektsii kognitivnyh narushenij u bol'nyh s serdechno-sosudistymi zabolevanijami // Consilium Medicum. – 2009; 11 (9): 41–5.
  16. Gan'kina O.A. i dr. Vlijanie piribedila na umerennye kognitivnye narushenija pri distsirkuljatornoj entsefalopatii // Zhurnal nevrol. i psihi-atr. im. Korsakova. (Gerontologija). – 2014; 6 (2): 61–6.
  17. Millan M. et al. The antiparkinsonian agent, piribedil, possesses a distinctive profile of dopamine D2/D3-agonist and alpha 2-antagonist properties: a multivariate comparison to other anti-parkinsonian agents at recombinant, human monoaminergic receptors // Mov. Disord. – 2002; 17 (Suppl. 5): S28.